Analysts highlight Insmed (INSM), Cogent Biosciences (COGT), Structure Therapeutics (GPCR), ImmunityBio (IBRX), Travere Therapeutics (TVTX), and Relay Therapeutics (RLAY) as their preferred biotech investments based on product pipelines and recent milestones.
Investor frenzy for SpaceX IPO may overwhelm concerns about losses, governance Source link
JHVEPhoto Eli Lilly (LLY) announced on Thursday that retatrutide, its next-gen obesity therapy targeting GIP,…
U.S. federal debt hits 100% of GDP, but Washington keeps spending Source link